What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2020-11-12 compared with 2020-05-13 · 31 added, 17 removed, 2 unchanged (96% of the section changed)

Other Information.

13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer*

13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer*

1350 Certification of Chief Executive Officer**

1350 Certification of Chief Financial Officer**

INSTANCE DOCUMENT

TAXONOMY EXTENSION SCHEMA DOCUMENT

TAXONOMY EXTENSION CALCULATION LINKBASE

TAXONOMY EXTENSION LABELS LINKBASE

TAXONOMY EXTENSION PRESENTATION LINKBASE

management contract or compensatory plan.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned thereunto duly authorized.

Pharmaceuticals, Inc.

On November 11, 2020, our Board of Directors (the “Board”) approved the terms of the First Amended Executive Employment Agreement, by and between Saiid Zarrabian and Kintara Therapeutics, Inc., including (i) that Mr.

Zarrabian will be eligible to receive an annual (fiscal year) performance bonus of up to fifty percent (50%) of his base salary, subject to the achievement of performance targets or criteria established by the Board for such year in consultation with Mr.

Zarrabian and (ii) that in the event of overachievement of such targets or criteria for a given fiscal year, the Board may increase the bonus for such year to up to an additional twenty-five percent (25%) of Mr.

Zarrabian’s base salary.

In addition, on November 11, 2020, the Board approved the acceleration of vesting of 279,675 stock options to purchase shares of our common stock previously granted to Mr.

Zarrabian on September 5, 2019, and which have an exercise price of $0.61 per share.

First Amended Executive Employment Agreement, by and between Kintara Pharmaceuticals, Inc.

and Saiid Zarrabian†

Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **

Certification of principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **

XBRL Instance Document *

XBRL Taxonomy Extension Schema Document *

XBRL Taxonomy Extension Calculation Linkbase *

XBRL Taxonomy Extension Definition Linkbase *

XBRL Taxonomy Extension Labels Linkbase *

XBRL Taxonomy Extension Presentation Linkbase *

Filed herewith

Furnished herewith

Exhibit is a management contract or compensatory plan or arrangement.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Kintara Therapeutics, Inc.

November 12, 2020

/s/ Saiid Zarrabian

Saiid Zarrabian

Executive Officer

Executive Officer)

Financial Officer

Financial and Accounting Officer)

Chief Executive Officer

(Principal Executive Officer)

November 12, 2020

/s/ Scott Praill

Chief Financial Officer

(Principal Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information